Janney Cuts Price Target on Cara Therapeutics (CARA) as UP is Delayed

March 11, 2016 10:12 AM

Janney Capital maintained a Buy rating on Cara Therapeutics (NASDAQ: CARA), and cut the price target to $18.00 (from $23.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found